Alkermes to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) to Participate in Fireside Chat at Jefferies London Healthcare Conference on Nov. 14, 2023

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14, 2023 at 12:00 p.m. ET (5:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-jefferies-london-healthcare-conference-301980646.html

SOURCE Alkermes plc

FAQ

What is the latest announcement from Alkermes plc (Nasdaq: ALKS)?

Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 14, 2023.

When and where can the live webcast be accessed?

The live webcast can be accessed under the Investors tab on www.alkermes.com on Nov. 14, 2023 at 12:00 p.m. ET (5:00 p.m. GMT) and will be archived for 14 days.